Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Holdings Raised by American Century Companies Inc.

American Century Companies Inc. lifted its holdings in Pieris Pharmaceuticals Inc (NASDAQ:PIRS) by 37.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 650,725 shares of the biotechnology company’s stock after buying an additional 177,569 shares during the quarter. American Century Companies Inc. owned approximately 1.20% of Pieris Pharmaceuticals worth $1,731,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC grew its position in shares of Pieris Pharmaceuticals by 3.3% in the 4th quarter. Acadian Asset Management LLC now owns 2,238,020 shares of the biotechnology company’s stock worth $5,955,000 after buying an additional 70,793 shares during the period. Nantahala Capital Management LLC grew its position in shares of Pieris Pharmaceuticals by 113.6% in the 4th quarter. Nantahala Capital Management LLC now owns 1,358,100 shares of the biotechnology company’s stock worth $3,613,000 after buying an additional 722,255 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Pieris Pharmaceuticals by 433.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 769,551 shares of the biotechnology company’s stock worth $2,047,000 after buying an additional 625,351 shares during the period. Wedge Capital Management L L P NC grew its position in shares of Pieris Pharmaceuticals by 56.0% in the 4th quarter. Wedge Capital Management L L P NC now owns 425,016 shares of the biotechnology company’s stock worth $1,131,000 after buying an additional 152,559 shares during the period. Finally, Vanguard Group Inc grew its position in shares of Pieris Pharmaceuticals by 13.6% in the 3rd quarter. Vanguard Group Inc now owns 370,616 shares of the biotechnology company’s stock worth $2,076,000 after buying an additional 44,335 shares during the period. 69.74% of the stock is currently owned by hedge funds and other institutional investors.

PIRS stock traded up $0.12 during trading on Friday, hitting $3.31. 799,700 shares of the stock traded hands, compared to its average volume of 353,142. Pieris Pharmaceuticals Inc has a 1 year low of $2.39 and a 1 year high of $6.55. The company has a market capitalization of $151.39 million, a price-to-earnings ratio of -6.62 and a beta of 1.78.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.05). The company had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.92 million. Pieris Pharmaceuticals had a negative net margin of 91.93% and a negative return on equity of 54.54%. As a group, analysts anticipate that Pieris Pharmaceuticals Inc will post -0.81 EPS for the current year.

Several analysts recently commented on PIRS shares. Zacks Investment Research raised shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research report on Friday, April 19th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective (up from $5.00) on shares of Pieris Pharmaceuticals in a research report on Friday. Finally, ValuEngine raised shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Pieris Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.13.

TRADEMARK VIOLATION NOTICE: “Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Holdings Raised by American Century Companies Inc.” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/pieris-pharmaceuticals-inc-pirs-shares-bought-by-american-century-companies-inc.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Read More: Understanding Market Liquidity

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.